Efficacy of topical cysteamine in nephropathic cystinosis

被引:12
|
作者
Al-Hemidan, Amal [1 ]
Shoughy, Samir S. [2 ,3 ]
Kozak, Igor [4 ]
Tabbara, Khalid F. [2 ,3 ,5 ,6 ]
机构
[1] Habib Med Grp, Ophthalmol Dept, Riyadh, Saudi Arabia
[2] Eye Ctr, Dept Ophthalmol, Riyadh, Saudi Arabia
[3] Eye Fdn Res Ophthalmol, Riyadh, Saudi Arabia
[4] King Khalid Eye Specialist Hosp, Riyadh, Saudi Arabia
[5] King Saud Univ, Dept Ophthalmol, Coll Med, Riyadh, Saudi Arabia
[6] Johns Hopkins Univ, Sch Med, Wilmer Ophthalmol Inst, Baltimore, MD 21205 USA
关键词
CORNEAL CRYSTALS; CLINICAL-TRIAL; MANIFESTATIONS; THERAPY; DISEASE;
D O I
10.1136/bjophthalmol-2016-309278
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose The aim of this study is to evaluate the efficacy of topical cysteamine 0.55% eye drops in the treatment of corneal cystine crystal deposits in patients with nephropathic cystinosis. Methods Thirty-two patients with nephropathic cystinosis were prospectively included in the study. Patients with corneal cystinosis were treated with topical cysteamine 0.55% eye drops. They were examined before treatment, on each monthly visit and after treatment at the last follow-up. Photophobia was classified as grade 0 (none) for no photophobia, grade 1 (mild) for photophobia in bright light, grade 2 (moderate) for photophobia in room light and grade 3 (severe) for photophobia in dim light. Corneal cystine crystals were graded as grade 0=none, grade 1=1-10 crystals/mm(2), grade 2=11-50 crystals/mm(2), grade 3=more than 50 crystals/mm(2). The main outcome measure was evaluation of photophobia and resolution of corneal cystine crystals. Results There were 13 male and 19 female patients. The mean age was 8 years with an age range of 8 months to 19 years. The mean follow-up period was 4.1 years with a range of 2-8 years. Improvement of photophobia was not clinically significant in symptomatic patients. Patients displayed statistically significant worsening of corneal cystine deposits during the follow-up period. Conclusions This study has shown that topical 0.55% cysteamine eye drops may have limited effects in decreasing the corneal cystine deposits in patients with severe forms of nephropathic cystinosis.
引用
收藏
页码:1234 / 1237
页数:4
相关论文
共 50 条
  • [21] ADVERSE REACTIONS TO ORAL CYSTEAMINE USE IN NEPHROPATHIC CYSTINOSIS
    CORDEN, BJ
    SCHULMAN, JD
    SCHNEIDER, JA
    THOENE, JG
    [J]. DEVELOPMENTAL PHARMACOLOGY AND THERAPEUTICS, 1981, 3 (01): : 25 - 30
  • [22] Population pharmacokinetics and pharmacodynamics of cysteamine in nephropathic cystinosis patients
    Bouazza, Naim
    Treluyer, Jean-Marc
    Ottolenghi, Chris
    Urien, Saik
    Deschenes, Georges
    Ricquier, Daniel
    Niaudet, Patrick
    Chadefaux-Vekemans, Bernadette
    [J]. ORPHANET JOURNAL OF RARE DISEASES, 2011, 6
  • [23] USE OF CYSTEAMINE IN THE TREATMENT OF NEPHROPATHIC CYSTINOSIS - A PROGRESS REPORT
    CORDEN, BJ
    SCHULMAN, JD
    SCHNEIDER, JA
    THOENE, JG
    [J]. PEDIATRIC RESEARCH, 1980, 14 (04) : 465 - 465
  • [24] EFFICACY AND SAFETY OF CYSTEAMINE HYDROCHLORIDE GEL FOR TOPICAL TREATMENT OF OCULAR CYSTINOSIS
    Niaudet, P.
    Labbe, A.
    Baudouin, C.
    Charbit, M.
    Guest, G.
    Loirat, C.
    Brion, G.
    Paglionc, M.
    [J]. PEDIATRIC NEPHROLOGY, 2009, 24 (09) : 1854 - 1854
  • [25] SUCCESSFUL USE OF TOPICAL CYSTEAMINE IN CYSTINOSIS
    Macario, M. C.
    Torres, A.
    Tavares, R.
    Cunha, L.
    [J]. JOURNAL OF INHERITED METABOLIC DISEASE, 2011, 34 : S87 - S87
  • [26] LONG-TERM TREATMENT OF INFANTILE NEPHROPATHIC CYSTINOSIS WITH CYSTEAMINE
    DASILVA, VA
    ZURBRUGG, RP
    LAVANCHY, P
    BLUMBERG, A
    SUTER, H
    WYSS, SR
    LUTHY, CM
    OETLIKER, OH
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (23): : 1460 - 1463
  • [27] ATTENUATION BUT NOT PREVENTION OF RENAL FANCONI SYNDROME BY CYSTEAMINE IN NEPHROPATHIC CYSTINOSIS
    ADAMSON, M
    SCHNEIDER, JA
    BERNARDINI, I
    REZNIK, VM
    ADELMAN, R
    GAHL, W
    [J]. PEDIATRIC RESEARCH, 1989, 25 (04) : A334 - A334
  • [28] FAILURE OF CYSTEAMINE TO PREVENT RENAL FANCONI SYNDROME IN NEPHROPATHIC CYSTINOSIS
    REZNIK, VM
    ADAMSON, M
    BERNARDINI, I
    ADELMAN, R
    GAHL, W
    SCHNEIDER, JA
    [J]. CLINICAL RESEARCH, 1989, 37 (01): : A218 - A218
  • [29] Nephropathic cystinosis - Posterior segment manifestations and effects of cysteamine therapy
    Tsilou, Ekaterini T.
    Rubin, Benjamin I.
    Reed, George
    Caruso, Rafael C.
    Iwata, Fumino
    Balog, Joan
    Gahl, William A.
    Kaiser-Kupfer, Muriel I.
    [J]. OPHTHALMOLOGY, 2006, 113 (06) : 1002 - 1009
  • [30] A systematic literature review of cysteamine bitartrate in the treatment of nephropathic cystinosis
    Medic, Goran
    van der Weijden, Miriam
    Karabis, Andreas
    Hemels, Michiel
    [J]. CURRENT MEDICAL RESEARCH AND OPINION, 2017, 33 (11) : 2065 - 2076